Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities

Bénedith Oben(Jessa Hospital), Guy Froyen(Jessa Hospital), Kylee Maclachlan(Memorial Sloan Kettering Cancer Center), Daniel Leongamornlert(Wellcome Sanger Institute), Federico Abascal(Wellcome Sanger Institute), Binbin Zheng-Lin(Memorial Sloan Kettering Cancer Center), Venkata Yellapantula(Memorial Sloan Kettering Cancer Center), Andriy Derkach(Memorial Sloan Kettering Cancer Center), Ellen Geerdens(Jessa Hospital), Benjamin Diamond(Memorial Sloan Kettering Cancer Center), Ingrid Arijs(VIB-KU Leuven Center for Cancer Biology), Brigitte Maes(Jessa Hospital), Kimberly Vanhees(Jessa Hospital), Malin Hultcrantz(Memorial Sloan Kettering Cancer Center), Elisabet E. Manasanch(The University of Texas MD Anderson Cancer Center), Dickran Kazandjian(National Institutes of Health), Alexander M. Lesokhin(Memorial Sloan Kettering Cancer Center), Ahmet Doǧan(Memorial Sloan Kettering Cancer Center), Yanming Zhang(Memorial Sloan Kettering Cancer Center), Aneta Mikulášová(Newcastle University), Brian A. Walker(Indiana University), Gareth J. Morgan(NYU Langone Health), Peter J. Campbell(Wellcome Sanger Institute), Ola Landgren(University of Miami), J L Rummens(Jessa Hospital), Niccolò Bolli(University of Milan), Francesco Maura(Memorial Sloan Kettering Cancer Center)
Nature Communications
March 25, 2021
Cited by 130Open Access
Full Text

Abstract

Multiple myeloma (MM) is consistently preceded by precursor conditions recognized clinically as monoclonal gammopathy of undetermined significance (MGUS) or smoldering myeloma (SMM). We interrogate the whole genome sequence (WGS) profile of 18 MGUS and compare them with those from 14 SMMs and 80 MMs. We show that cases with a non-progressing, clinically stable myeloma precursor condition (n = 15) are characterized by later initiation in the patient's life and by the absence of myeloma defining genomic events including: chromothripsis, templated insertions, mutations in driver genes, aneuploidy, and canonical APOBEC mutational activity. This data provides evidence that WGS can be used to recognize two biologically and clinically distinct myeloma precursor entities that are either progressive or stable.


Related Papers